Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$14.69 - $27.52 $146,900 - $275,200
-10,000 Reduced 34.08%
19,341 $532,000
Q1 2021

May 04, 2021

BUY
$16.27 - $41.26 $477,378 - $1.21 Million
29,341 New
29,341 $589,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $626M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Alaethes Wealth LLC Portfolio

Follow Alaethes Wealth LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alaethes Wealth LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alaethes Wealth LLC with notifications on news.